stockportfolio.pro
Stocks / BMY vs MCK
BMY vs MCK
Bristol-Myers Squibb Company and McKesson Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bristol-Myers Squibb Company (BMY) | McKesson Corporation (MCK) | |
|---|---|---|
| Market cap | $114.8B | $93.7B |
| Revenue (latest FY) | $48.19B | $403.43B |
| Net income (latest FY) | $7.05B | $4.76B |
| Revenue growth (5y CAGR) | 2.5% | 11.1% |
| Net margin | 14.6% | 1.2% |
| Return on equity | 38.2% | -219.2% |
| P/E ratio | 15.8 | 20.3 |
| Dividend yield | 4.4% | 0.4% |
| Profitable years (of last 10) | 8 | 9 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMY — free Open MCK — freeFrequently asked questions
Which is bigger, BMY or MCK?
Bristol-Myers Squibb Company is larger by market capitalization — $114.8B versus $93.7B.
Which grows faster, BMY or MCK?
Over the last five fiscal years, McKesson Corporation grew revenue faster — 11.1%/yr versus 2.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.